Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Boston Beer Company Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Boston Beer Company Inc trades at $176.79 (market cap $1.84B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 21.7× Boston Beer Company Inc's market cap. Which is the better fit depends on your goals.
| ALNY | SAM | |
|---|---|---|
Market Cap | $39.89B | $1.84B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $260.05 |
52-Week Low | $278.09 | $161.08 |
Enterprise Value | $38.15B | $1.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SAM trades at $176.79, up 1.1% on the day, amid a bearish technical signal but with a consensus analyst price target of $222.67 suggesting upside. Recent earnings show volatility with a Q1 2026 miss, while full-year 2025 net income improved to $108.47M. Cash flow remains positive, but 2026 revenue and profit projections indicate challenges. The company is investing in brand innovation and Beyond Beer expansion to drive growth.
The outlook is mixed; valuation ratios appear reasonable, and strategic initiatives support long-term potential, but near-term volume pressure and negative 2026 profit forecasts pose risks. Investor sentiment is cautious, with most analysts rating Hold. Key catalysts include execution on cost savings and brand momentum against a competitive backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
